Navigation Links
Aeterna Zentaris Reports Third Quarter 2010 Financial and Operating Results
Date:11/9/2010

age oncology drug development company currently investigating potential treatments for various cancers including colorectal, ovarian and endometrial cancer as well as multiple myeloma. The Company's innovative approach of "personalized medicine" means tailoring treatments to a patient's specific condition and to unmet medical needs. Aeterna Zentaris' deep pipeline is drawn from its proprietary discovery unit providing constant and long-term access to state-of-the-art therapeutic options. For more information please visit www.aezsinc.com. Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties that could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or by applicable law. Attachment: Financial
'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
2. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
3. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
4. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
5. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
6. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
7. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
8. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
9. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
10. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
11. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014  Next month, executives from clinical trial marketing ... events beginning with Patient-Centered Clinical Trials 2014 , to ... Boston , September 4-5. Patient recruitment experts Bonnie ... Fleishman will share insights on the benefits of employing ... tactics – from media to mobile apps – can be ...
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ( ... novel mid- to late-stage cardiovascular drug candidates, today ... its first round of financing. The Series A ... Hercules Bioventures with participation from investors that included ... executive, Dr. Larry Hsu , the founder ...
(Date:8/28/2014)... 28, 2014 A new market ... world is available from Strategic Consulting, Inc., the ... Industrial Microbiology Market Review, Fourth Edition: Global Review ... (IMMR—4) tracks and compares microbiology test volumes, market ... Europe and Asia, and forecasts future volumes and ...
(Date:8/28/2014)... 28, 2014 Supplementing their complete ... promotion for Eppendorf Safe Lock Centrifuge Tubes ... the highest quality tubes at an affordable price. ... customers doing chemical, medical, pharmaceutical, and life science ... not regularly able to afford Eppendorf products. , ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3
... Its that time again for the half-year roundup of stock market ... you recall the results from the first quarter, it was pretty ... percent , Nasdaq National Market down 8 percent , Nasdaq Biotech ... isnt a great trend. As you can see below, the results ...
... International, a supplier of automatic identification and data collection ... 4.0 of their NiceLabel software. , ,The new versions ... radio frequency identification (RFID) tags, as well as an ... with Windows programs such as Microsoft Access, Windows Event ...
... As NASA works to get the Space Shuttle Discovery ... be monitored by NASA flight surgeons using GE Healthcare's ... health information will enable NASA to monitor and track the ... the sharing also of information with experts located outside NASA's ...
Cached Biology Technology:Midwest large cap life sciences mostly outperform market 2Midwest large cap life sciences mostly outperform market 3
(Date:8/28/2014)... for your neighbors than traditional cigarettes, but still ... new study from USC. , Scientists studying secondhand ... in exposure to harmful particles, with close-to-zero exposure ... some harmful metals in second-hand e-cigarette smoke were ... smoke contains high levels of polycyclic aromatic hydrocarbons ...
(Date:8/28/2014)... (August 28, 2014) Researchers at the University of ... muscular dystrophy (FSHD) to be used for muscle regeneration ... potential therapies for FSHD. , The research is published ... Reports . , There is no treatment for FSHD, ... common type of muscular dystrophy. FSHD is an unusual ...
(Date:8/28/2014)... on-off switch for Streptomyces , a group of ... world,s naturally derived antibiotic medicines. , Their hope ... to manipulate this switch to make nature,s antibiotic factory ... in Cell , found that a unique interaction ... protein called BldD ultimately controls whether a bacterium spends ...
Breaking Biology News(10 mins):Second-hand e-cig smoke compared to regular cigarette smoke 2UMN researchers find animal model for understudied type of muscular dystrophy 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... the wind, but a new study in the October 14th ... confirms that they are anything but drifters. A previous ... evidence that Silver Y moths rely on a sophisticated internal ... destination within a matter of days. Now, the research team ...
... mouse heart has an astounding capacity to regenerate, ... The research, published by Cell Press in the ... Cell , describes the previously unrecognized potential of ... compensatory proliferation of healthy cells. Disorders of ...
... why people who eat more fruit and vegetables may gain ... that a fragment released from pectin, found in all fruits ... 3 (Gal3), a protein that plays a role in all ... effects of foods are based on population studies," says Professor ...
Cached Biology News:Migratory moths may hitch their rides, but they're anything but drifters 2Embryonic heart exhibits impressive regenerative capacity 2Pectin power 2
BD BioCoat Laminin 150 mm Culture Dishes...
Polymerase (RNA) II (DNA directed) polypeptide L...
MAb to Desmoplakin I & II Desmoplakin I & II...
Chicken Anti-Human DNA-directed RNA Polymerase II 7.6 Kd Polypeptide (POLR2L Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: ELISA, Western Blot...
Biology Products: